A Lesion on the Pancreas: Types and Treatments

Pancreatic lesions are abnormal growths found in or on the pancreas, and they range from harmless fluid-filled sacs to aggressive cancers. Many are discovered by accident during imaging for an unrelated problem, which leaves people understandably anxious about what the finding means. The reality is that the word “lesion” tells you almost nothing on its own. What matters is whether the growth is cystic or solid, whether it produces mucin, how fast its cells divide, and where exactly in the pancreas it sits. Those details determine whether you need surgery, long-term monitoring, chemotherapy, or nothing at all.

How Common Are Incidental Pancreatic Lesions

Improvements in imaging technology over the past two decades mean that CT and MRI scans pick up pancreatic findings that would have gone unnoticed a generation ago. A large systematic review pooling data from over 65,000 people found that roughly one in six adults has a pancreatic cystic lesion, with prevalence climbing steeply with age: about 9% among people in their fifties, 18% in their sixties, about a quarter in their seventies, and close to 40% in people aged 80 and above.¹ Most of these lesions are small, under a centimeter, and will never cause symptoms or become cancerous. But the discovery of a cyst or mass on your pancreas almost always triggers a workup to determine exactly what it is.

MRI tends to catch more of these lesions than CT does. One study comparing both modalities in overlapping populations found a detection rate of about 2% on CT versus about 3.3% on MRI, with detection increasing at older ages on both.² The difference partly reflects MRI’s superior soft-tissue contrast, which is why MRI is often the preferred follow-up tool once a cyst is detected.

Cystic Lesions and Why Mucin Matters

Pancreatic cysts fall into several categories, but the single most important distinction is whether the cyst lining produces mucin. Mucinous cysts carry a risk of eventually transforming into cancer; non-mucinous cysts almost never do. That one fact drives the entire management approach.³

The three most common types of cystic neoplasm are intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), and serous cystic neoplasms (SCNs). Their behavior varies enormously.⁴

IPMNs: These grow inside the pancreatic duct system, produce mucin, and are the most frequently encountered cystic neoplasms. Some IPMNs remain stable for years; others progress through stages of increasingly abnormal cells toward invasive cancer. Features that raise alarm include solid nodules 5 mm or larger inside the cyst, rapid growth, and positive cytology on fluid sampling.⁵
MCNs: These occur almost exclusively in women and tend to appear in the body or tail of the pancreas. Like IPMNs, they produce mucin and have malignant potential, but they do not communicate with the pancreatic duct. Surgical removal is curative in the vast majority of cases.
SCNs: These are non-mucinous and almost always benign. They often have a characteristic “honeycomb” appearance on imaging. Unless they grow large enough to cause symptoms by pressing on nearby structures, they rarely require treatment.

Not every cyst is a neoplasm. Pseudocysts, which arise after bouts of pancreatitis, are fluid collections surrounded by fibrous tissue rather than a true cell lining. They are not precancerous and are managed differently, usually resolving on their own or being drained if they cause pain or infection.

Solid Pancreatic Lesions

Solid masses on the pancreas raise a different set of concerns. The most feared is pancreatic ductal adenocarcinoma, which accounts for the large majority of pancreatic cancers. These tumors are staged by size, lymph node involvement, and whether cancer has spread to distant organs. From a treatment-planning standpoint, the key question is operability: tumors are categorized as resectable, borderline resectable, locally advanced, or metastatic.⁶ Only a fraction of patients are diagnosed early enough for surgery to be an option, which is why staging is so consequential.

Pancreatic neuroendocrine tumors (sometimes called PNETs) are a distinct and much less common category. They arise from hormone-producing cells in the pancreas and behave very differently from adenocarcinoma. Some are “functioning,” meaning they secrete hormones and cause recognizable syndromes such as low blood sugar from an insulinoma. Most, however, are non-functioning and discovered incidentally or because they’ve grown large enough to press on something.⁷ These tumors are graded by how quickly their cells divide. Low-grade neuroendocrine tumors tend to grow slowly and have a far better prognosis than adenocarcinoma, while high-grade tumors can be aggressive and difficult to treat.⁸

When a Lesion Mimics Cancer

One of the trickiest scenarios is autoimmune pancreatitis, a benign inflammatory condition that can look almost identical to pancreatic cancer on imaging and even during clinical evaluation.⁹ Patients may present with jaundice and a mass visible on a scan, leading clinicians to suspect the worst. The distinction is critical because autoimmune pancreatitis responds to steroid therapy and does not require major surgery. Certain imaging features and blood markers help differentiate the two, but in ambiguous cases a biopsy is needed to avoid an unnecessary operation.

CT and MRI each bring different strengths to this problem. CT excels at detecting calcifications, vascular invasion patterns, and pseudocysts, while MRI is better at soft-tissue characterization and measuring water-molecule diffusion, which differs between cancer and inflammatory masses.¹⁰ In practice, most specialists use both tools in tandem when the diagnosis is uncertain.

Getting a Tissue Diagnosis

Imaging can narrow the possibilities, but a definitive answer often requires a sample of cells or tissue. The standard approach is endoscopic ultrasound-guided tissue acquisition, where a thin needle is passed through the wall of the stomach or duodenum directly into the pancreatic lesion under ultrasound guidance. Two techniques are used: fine needle aspiration, which suctions out loose cells, and fine needle biopsy, which captures a small core of tissue preserving the lesion’s architecture.

Both methods deliver high diagnostic accuracy for pancreatic masses. A meta-analysis of randomized trials found that fine needle biopsy had a modestly higher accuracy than aspiration alone.¹¹ Another meta-analysis found the two approaches comparable in diagnostic accuracy overall.¹² The practical upshot is that both work well, and the choice often depends on what the pathologist needs and what equipment is available.

For cystic lesions, fluid can be aspirated during the same procedure and sent for biochemical analysis. Measuring carcinoembryonic antigen (CEA) levels in the cyst fluid is one of the main ways to tell mucinous cysts from non-mucinous ones. A CEA level above roughly 200 ng/mL is highly specific for a mucinous cyst, though its sensitivity is moderate, meaning some mucinous cysts still register below that threshold.¹³ Amylase levels help identify pseudocysts, which tend to have very high amylase concentrations compared to true neoplasms.¹⁴ Neither marker alone is perfect, but together they can substantially sharpen the diagnosis.¹⁵

Surgical Treatment Options

When a pancreatic lesion needs to come out, the type of surgery depends on where in the pancreas it sits. Tumors in the head of the pancreas are typically treated with a Whipple procedure (pancreaticoduodenectomy), one of the most complex abdominal operations performed. It removes the head of the pancreas along with parts of the small intestine, bile duct, and sometimes a portion of the stomach. Tumors in the body or tail are removed with a distal pancreatectomy, which is a less extensive procedure. The Whipple procedure offers better long-term survival for head-of-pancreas tumors but carries a higher complication rate, including delayed stomach emptying and pancreatic fistulas. Distal pancreatectomy is simpler surgically but tends to have less favorable survival outcomes, partly because tumors in the body and tail are often caught at a later stage.¹⁶

For benign or low-grade tumors, surgeons sometimes use parenchyma-sparing techniques that remove the lesion while preserving as much healthy pancreatic tissue as possible. Enucleation, which shells out the tumor from surrounding tissue, is one such approach. Evidence from a pooled analysis of published cases shows that enucleation carries very low mortality (well under 1%) and preserves endocrine and exocrine function far better than standard resections. The trade-off is a higher rate of pancreatic fistula, which is a leak of pancreatic juice from the surgical site, though this complication is usually manageable.¹⁷ Tumor recurrence after enucleation is uncommon, and the approach is considered safe for appropriately selected patients.¹⁸

Chemotherapy for Pancreatic Adenocarcinoma

For advanced pancreatic ductal adenocarcinoma, chemotherapy is the backbone of treatment. The combination regimen known as FOLFIRINOX transformed the landscape when a landmark trial showed it nearly doubled median survival compared to gemcitabine alone, with patients on FOLFIRINOX living a median of about 11 months versus roughly 7 months on gemcitabine for metastatic disease.¹⁹ The gains come at a cost: FOLFIRINOX produces more side effects, including a roughly 5% rate of febrile neutropenia, so it is typically reserved for patients who are fit enough to tolerate it.

FOLFIRINOX has also been used before surgery (neoadjuvant therapy) in patients with localized but borderline resectable tumors, with the goal of shrinking the tumor enough to make an operation feasible. A large retrospective study of this approach found that patients who went on to have surgery after FOLFIRINOX had a median survival exceeding three years.²⁰ Even for locally advanced disease that was not surgically resectable, median survival with FOLFIRINOX was close to 19 months, a meaningful improvement over historical expectations.

Surveillance Instead of Surgery

Many pancreatic cysts never require an operation. Guidelines from multiple international groups converge on a surveillance strategy that tailors the frequency of imaging to the type of cyst, its size, and whether it shows worrisome features. For a suspected IPMN that does not meet criteria for surgery, the standard protocol involves imaging every six months in the first year, then annually as long as the patient remains a surgical candidate. MCNs under 4 cm without concerning features follow a similar schedule. Serous cystic neoplasms need even less attention: an asymptomatic SCN may be re-imaged at one year and then followed only if symptoms develop. Cysts of unclear type smaller than 15 mm are typically rechecked after a year, and if stable for three years, the interval can stretch to every two years.²¹ MRI and endoscopic ultrasound are the preferred surveillance modalities, as they avoid repeated radiation exposure from CT scans.

Life After Pancreatic Surgery

Removing part of the pancreas has lasting metabolic consequences because the organ produces both digestive enzymes and insulin. A multicenter prospective study found that about three-quarters of patients developed exocrine pancreatic insufficiency (difficulty digesting food, especially fats) within six months of a Whipple procedure, versus about a fifth after distal pancreatectomy. New-onset diabetes appeared in roughly 30% of patients overall.²² A cross-sectional study of longer-term survivors found that about 40% reported exocrine insufficiency and about 14% had new diabetes, with enzyme supplements relieving symptoms in about half of those affected.²³

These numbers underscore why parenchyma-sparing techniques are preferred when the tumor’s biology allows it. Preserving even a modest amount of pancreatic tissue can meaningfully reduce the likelihood of enzyme and insulin deficiency after surgery.²⁴

Emerging Minimally Invasive Ablation

Not everyone with a worrisome pancreatic cyst or small tumor is a good candidate for major surgery. Endoscopic ultrasound-guided ablation is an emerging alternative that treats lesions from the inside using chemical agents (such as alcohol injected into a cyst) or heat (radiofrequency ablation). These procedures are performed through the same endoscopic route used for biopsies, with no external incisions.²⁵

Early results are encouraging but still modest. Pooled data on radiofrequency ablation for pancreatic cysts showed complete resolution in about a third of treated cysts over roughly ten months of follow-up, with side effects generally limited to mild, short-lived abdominal pain.²⁶ Pilot studies of the same technique for small neuroendocrine tumors showed changes in tumor blood supply and central tissue death after ablation, also without major complications.²⁷ These approaches are not yet standard of care and are largely performed in research settings, but they offer a glimpse of less invasive options for selected patients.

Genetic Risk and Screening

A small but important fraction of pancreatic cancers run in families, driven by inherited mutations in DNA-repair genes. The best-studied are BRCA2, PALB2, and ATM, but mutations in CDKN2A, STK11, the mismatch-repair genes associated with Lynch syndrome, and TP53 also increase pancreatic cancer risk to varying degrees.²⁸ Hereditary pancreatitis, caused by mutations in genes like PRSS1, carries one of the highest lifetime risks of pancreatic cancer of any inherited condition.²⁹

For people with a strong family history or a known cancer-predisposition syndrome, current recommendations call for pancreatic screening starting in middle age, typically with annual MRI or endoscopic ultrasound. The goal is to catch cancers or high-risk precursor lesions at a stage when surgery is still curative. Multigene panel testing is now available and recommended for individuals who meet criteria, though real-world uptake of testing still has room to grow.³⁰

The Psychological Toll of Living Under Surveillance

Being told you have a cyst on your pancreas and that it needs to be watched indefinitely takes a real psychological toll, even when the objective risk of cancer is low. A prospective study comparing IPMN surveillance patients with the general population found that those under surveillance reported higher levels of anxiety, depression, and physical symptoms like somatic complaints.³¹ The researchers described this as a “Sword of Damocles” effect, the persistent sense that something dangerous is hanging over you.

Other studies paint a slightly more optimistic picture. A survey of patients in or approaching pancreatic cyst surveillance found that the vast majority viewed the program positively, with over 80% saying it reduced their worry about developing cancer and over 90% considering it a good method for detecting problems. Still, those already in the program reported more negative effects than those who had not yet started, including worse sleep and a sense that the follow-up was burdensome.³² A qualitative study found that uncertainty was the dominant experience, with patients describing emotional swings from near-panic to little concern depending on where they were in the surveillance cycle.³³ Clear communication from clinicians about what a cyst diagnosis actually means and what the surveillance plan entails can go a long way toward easing that uncertainty.

Artificial Intelligence in Pancreatic Imaging

One area drawing significant research attention is the use of machine learning to improve the accuracy and speed of pancreatic lesion diagnosis on imaging. Radiomics, which involves extracting large numbers of quantitative features from CT or MRI scans and feeding them into algorithms, has shown promise in distinguishing between different types of pancreatic lesions.³⁴ A recent study testing multiple machine learning models found that the best-performing algorithm could differentiate among three pancreatic tumor types with an area under the curve above 0.95 in a validation set, suggesting near-expert-level diagnostic accuracy.³⁵ These tools are not ready for standalone clinical use, but they could eventually assist radiologists in flagging suspicious lesions earlier and reducing the number of ambiguous or missed diagnoses.